SG11201903099QA - Wt1 targeting dna vaccine for combination therapy - Google Patents
Wt1 targeting dna vaccine for combination therapyInfo
- Publication number
- SG11201903099QA SG11201903099QA SG11201903099QA SG11201903099QA SG11201903099QA SG 11201903099Q A SG11201903099Q A SG 11201903099QA SG 11201903099Q A SG11201903099Q A SG 11201903099QA SG 11201903099Q A SG11201903099Q A SG 11201903099QA SG 11201903099Q A SG11201903099Q A SG 11201903099QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- treatment
- pct
- combination therapy
- gitr
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 230000008685 targeting Effects 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 108020004414 DNA Proteins 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 abstract 2
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 2
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 2
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 abstract 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 abstract 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract 2
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 2
- 102000053602 DNA Human genes 0.000 abstract 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 abstract 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 abstract 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 abstract 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 abstract 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 abstract 2
- 102000017578 LAG3 Human genes 0.000 abstract 2
- 101150030213 Lag3 gene Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- -1 OX-40 Proteins 0.000 abstract 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 abstract 2
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 abstract 2
- 241000607142 Salmonella Species 0.000 abstract 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 abstract 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 abstract 2
- 230000002238 attenuated effect Effects 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract 2
- 208000008383 Wilms tumor Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16197322 | 2016-11-04 | ||
| PCT/EP2017/078124 WO2018083209A1 (en) | 2016-11-04 | 2017-11-03 | Wt1 targeting dna vaccine for combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903099QA true SG11201903099QA (en) | 2019-05-30 |
Family
ID=57249707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903099QA SG11201903099QA (en) | 2016-11-04 | 2017-11-03 | Wt1 targeting dna vaccine for combination therapy |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230158133A1 (ko) |
| EP (1) | EP3534935A1 (ko) |
| JP (1) | JP2019533698A (ko) |
| KR (1) | KR20190082227A (ko) |
| CN (1) | CN109906087A (ko) |
| AU (1) | AU2017353432A1 (ko) |
| BR (1) | BR112019009003A2 (ko) |
| CA (1) | CA3041375A1 (ko) |
| IL (1) | IL265684A (ko) |
| MX (1) | MX2019005212A (ko) |
| RU (1) | RU2019112977A (ko) |
| SG (1) | SG11201903099QA (ko) |
| WO (1) | WO2018083209A1 (ko) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230121528A1 (en) | 2020-01-13 | 2023-04-20 | Vaximm Ag | Salmonella-based dna vaccines in combination with an antibiotic |
| EP3922255A1 (en) * | 2020-06-10 | 2021-12-15 | Prokarium Limited | Cancer therapy |
| KR20230066249A (ko) * | 2021-11-05 | 2023-05-15 | 전남대학교산학협력단 | 살모넬라 균주 및 면역관문억제제를 유효성분으로 포함하는 암의 예방 또는 치료용 약학조성물 |
| KR20240081501A (ko) * | 2022-11-14 | 2024-06-10 | 전남대학교산학협력단 | 암의 치료용 면역증강 살모넬라 균주 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107090029B (zh) * | 2010-11-11 | 2021-07-13 | 港大科桥有限公司 | 可溶性 pd-1变体、融合构建体及其用途 |
| WO2012149364A1 (en) * | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
| NO337687B1 (no) | 2011-07-08 | 2016-06-06 | Norsk Elektro Optikk As | Hyperspektralt kamera og metode for å ta opp hyperspektrale data |
| CN104519908B (zh) * | 2012-07-05 | 2020-10-30 | 万科斯蒙股份有限公司 | 用于胰腺癌患者的dna疫苗 |
| CA2899577C (en) * | 2013-04-03 | 2023-10-17 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| AU2014256457B2 (en) | 2013-04-25 | 2018-02-22 | Vaximm Ag | Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene WT1 |
| RU2016129044A (ru) * | 2013-12-18 | 2018-01-23 | Факсимм Гмбх | Новая вакцина днк, нацеленная на мезотелин, для иммунотерапии рака |
| US10975112B2 (en) * | 2015-06-16 | 2021-04-13 | Hangzhou Dac Biotech Co., Ltd. | Linkers for conjugation of cell-binding molecules |
| US20180153976A1 (en) * | 2015-06-18 | 2018-06-07 | Vaximm Ag | Novel cmv pp65 targeting dna vaccine for cancer immunotherapy |
| AU2016278588B2 (en) * | 2015-06-18 | 2022-03-31 | Vaximm Ag | VEGFR-2 targeting DNA vaccine for combination therapy |
-
2017
- 2017-11-03 SG SG11201903099QA patent/SG11201903099QA/en unknown
- 2017-11-03 CN CN201780068135.3A patent/CN109906087A/zh active Pending
- 2017-11-03 RU RU2019112977A patent/RU2019112977A/ru not_active Application Discontinuation
- 2017-11-03 AU AU2017353432A patent/AU2017353432A1/en not_active Abandoned
- 2017-11-03 WO PCT/EP2017/078124 patent/WO2018083209A1/en unknown
- 2017-11-03 MX MX2019005212A patent/MX2019005212A/es unknown
- 2017-11-03 US US16/347,551 patent/US20230158133A1/en not_active Abandoned
- 2017-11-03 KR KR1020197014109A patent/KR20190082227A/ko unknown
- 2017-11-03 BR BR112019009003A patent/BR112019009003A2/pt not_active Application Discontinuation
- 2017-11-03 EP EP17797909.3A patent/EP3534935A1/en not_active Withdrawn
- 2017-11-03 JP JP2019523035A patent/JP2019533698A/ja active Pending
- 2017-11-03 CA CA3041375A patent/CA3041375A1/en not_active Abandoned
-
2019
- 2019-03-27 IL IL265684A patent/IL265684A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230158133A1 (en) | 2023-05-25 |
| RU2019112977A (ru) | 2020-12-04 |
| CN109906087A (zh) | 2019-06-18 |
| CA3041375A1 (en) | 2018-05-11 |
| IL265684A (en) | 2019-05-30 |
| BR112019009003A2 (pt) | 2019-07-16 |
| EP3534935A1 (en) | 2019-09-11 |
| WO2018083209A1 (en) | 2018-05-11 |
| MX2019005212A (es) | 2019-06-20 |
| JP2019533698A (ja) | 2019-11-21 |
| KR20190082227A (ko) | 2019-07-09 |
| AU2017353432A1 (en) | 2019-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201908787WA (en) | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap | |
| SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201903167QA (en) | Compounds and methods for reducing atxn3 expression | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201908784TA (en) | Improved antigen binding receptor formats | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201903099QA (en) | Wt1 targeting dna vaccine for combination therapy | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof |